What does Viridian Therapeutics, Inc. do?
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and…
What is Viridian Therapeutics, Inc.'s P/E and P/B ratio?
Viridian Therapeutics, Inc. has a P/E ratio of -6.7 and a P/B ratio of 3.90.
What is Viridian Therapeutics, Inc.'s debt-to-equity ratio?
Viridian Therapeutics, Inc. has a debt-to-equity ratio of 0.37.
How much does Viridian Therapeutics, Inc. owe compared with what it owns?
Viridian Therapeutics, Inc. owes $0.40 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Viridian Therapeutics, Inc.'s Positivity rank?
Viridian Therapeutics, Inc. is ranked #5,114 of 6,774 companies globally and #2,722 of 4,000 in United States on PositoAI, with a Positivity Score of 18,351.
Does Viridian Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Viridian Therapeutics, Inc..
Where can I read the latest news about Viridian Therapeutics, Inc.?
Recent headlines about Viridian Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Viridian Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Viridian Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.